Related Experiment Videos
Expression of gene MAGE-A4 in Reed-Sternberg cells
H Chambost1, N Van Baren, F Brasseur
1INSERM U119 and Unité d'Immunologie des Tumeurs, Institut Paoli Calmettes, Marseilles, France.
Abstract:
Genes of the MAGE-A family are expressed in several types of solid tumors but are silent in normal tissues with the exception of male germline cells, which do not carry HLA molecules.Therefore, peptides encoded by MAGE-A genes are strictly tumor-specific antigens that can be recognized by CTL and constitute promising targets for immunotherapy. The expression of 6 genes of the MAGE-A family was tested with reverse transcriptase-polymerase chain reaction in lymphoma samples. Among 38 samples of non-Hodgkin lymphoma, 1 anaplastic large cell lymphoma expressed genes MAGE-A1, -A2, -A3, -A4, and -A12, and 1 lymphoepithelioid T-cell lymphoma expressed gene MAGE-A4. Five of 18 samples (28%) from patients with Hodgkin disease expressed gene MAGE-A4. In tissue sections, staining by a monoclonal antibody that recognizes the MAGE-A4 protein was observed in 11 of 53 samples (21%) from patients with Hodgkin disease. In the positive samples, the Reed-Sternberg cells were strongly stained whereas the surrounding cells were not. These results indicate that Hodgkin disease may be a target for specific immunotherapy involving MAGE-A4 antigens.
Insights
MAGE-A4 antigen expression was detected in Hodgkin disease samples, suggesting its potential as a target for cancer immunotherapy. This finding opens new avenues for developing specific treatments for Hodgkin lymphoma.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- MAGE-A genes are tumor-specific antigens, ideal for cancer immunotherapy.
- These antigens are expressed in solid tumors but not in normal tissues (except male germ cells).
- Cytotoxic T lymphocytes (CTLs) recognize MAGE-A peptides, making them promising immunotherapy targets.
Purpose of the Study:
- To investigate the expression of MAGE-A family genes in lymphoma samples.
- To evaluate MAGE-A4 protein expression in Hodgkin disease.
- To assess the potential of MAGE-A4 as a target for Hodgkin lymphoma immunotherapy.
Main Methods:
- Reverse transcriptase-polymerase chain reaction (RT-PCR) was used to test MAGE-A gene expression in lymphoma samples.
- Monoclonal antibody staining was performed on tissue sections to detect MAGE-A4 protein.
- Analysis included samples of non-Hodgkin lymphoma and Hodgkin disease.
Main Results:
- MAGE-A gene expression was found in specific non-Hodgkin lymphoma subtypes.
- MAGE-A4 gene was expressed in 5 of 18 (28%) Hodgkin disease samples.
- MAGE-A4 protein was detected in 11 of 53 (21%) Hodgkin disease samples, specifically in Reed-Sternberg cells.
Conclusions:
- Hodgkin disease exhibits MAGE-A4 antigen expression.
- MAGE-A4 represents a potential tumor-specific target for immunotherapy in Hodgkin disease.
- These findings support the development of MAGE-A4-targeted immunotherapies for Hodgkin lymphoma.